Educational guide
GHRP-2 10mg Dosage Protocol | PeptideDosages.com
GHRP-2 (10 mg Vial) Dosage Protocol GHRP-2 (10 mg Vial) Dosage Protocol GHRP-2 Dosage Chart GHRP-2 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
GHRP-2 (10 mg Vial) Dosage Protocol
GHRP-2 (10 mg Vial) Dosage Protocol
GHRP-2 Dosage Chart
GHRP-2 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
GHRP-2 (pralmorelin) is a synthetic hexapeptide that potently stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus[1][2]. It has been used in clinical research as a diagnostic GH stimulant and in investigative treatment protocols for growth hormone deficiency[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read What Is GHRP-2? Mechanism, Benefits, Risks, and Alternatives.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
Weeks 1–2
100 mcg (0.1 mg)
3 units (0.03 mL)
Weeks 3–4
150 mcg (0.15 mg)
4.5 units (0.045 mL)
Weeks 5–8
200 mcg (0.2 mg)
6 units (0.06 mL)
Weeks 9–12 (optional)
250–300 mcg (0.25–0.3 mg)
7.5–9 units (0.075–0.09 mL)
Frequency: Inject once daily subcutaneously, typically before sleep to coincide with natural GH pulsatility[4]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Advanced / Aggressive Approach (Multiple Daily Dosing)
Published human research tested once-daily subcutaneous GHRP-2 over five days and documented response attenuation[4]. Treat the multiple-daily table below as a research calculation model, not as a schedule established by that study.
Phase 1 (Weeks 1–2)
2× daily
Phase 2 (Weeks 3–4)
Phase 3 (Weeks 5–8)
2–3× daily
Note: Total daily doses in the 600–900 mcg range (split across injections) have been studied but may accelerate GH response attenuation[4]. A 5‑days‑on/2‑days‑off cycling pattern may help maintain receptor sensitivity[7].
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration (once‑daily schedule).
Peptide Vials (GHRP-2, 10 mg each):
8 weeks ≈ 1 vial (~9.1 mg used)
12 weeks ≈ 2 vials (~15.4 mg used)
16 weeks ≈ 3 vials (~22.4 mg used)
Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes
16 weeks: 224 swabs → recommend 3 × 100‑count boxes